Meridian Bioscience Inc. (VIVO)
(Delayed Data from NSDQ)
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[VIVO]
Reports for Purchase
Showing records 1 - 20 ( 81 total )
Industry: Medical - Products
Merger Expected to Close on January 31, 2023; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Fiscal 3Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Meridian To be Acquired for $1.53B in Cash; Downgrading to Neutral with $34 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
qPCR Master Mixes For Monkeypox Ready to Ship; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Fiscal 2Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Record Financial Performance in F2Q22 Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Robust Performance in F1Q22; Reiterate Buy; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
F4Q21 and Fiscal-Year 2021 Results; Reiterate Buy; Modulating PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Multiple Air-Dryable qPCR Mixes Launched; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Industry: Medical - Products
COVID-19 Revenue Dwindles in F3Q21; Reiterate Buy; Reducing PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Accretive Diagnostic Business Acquired; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Revogene COVID-19 Assay EUA Application Resubmitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Solid F2Q21 Performance; FY21 Guidance Down; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
New Point-of-Care Molecular Test Mix Launched; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Revogene SARS-CoV-2 Test EUA Delayed; Reiterate Buy; Lowering PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Record Financial Performance in F1Q21; Reiterate Buy; Raising PT to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
NIH Grant Supports SARS-CoV-2 Test Production Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Products
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department